Gilead Sciences, Inc. $GILD Stock Holdings Cut by Triglav Investments D.O.O.

Triglav Investments D.O.O. cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 21.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 16,000 shares of the biopharmaceutical company’s stock after selling 4,387 shares during the quarter. Triglav Investments D.O.O.’s holdings in Gilead Sciences were worth $2,230,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the fourth quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC raised its position in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares in the last quarter. Quattro Advisors LLC bought a new stake in Gilead Sciences in the fourth quarter worth about $26,000. Wealth Preservation Advisors LLC lifted its holdings in Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in Gilead Sciences in the 4th quarter valued at about $28,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

GILD stock opened at $129.83 on Monday. Gilead Sciences, Inc. has a one year low of $107.75 and a one year high of $157.29. The firm has a 50-day moving average of $129.78 and a two-hundred day moving average of $135.03. The firm has a market capitalization of $161.19 billion, a PE ratio of 17.69 and a beta of 0.32. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same period last year, the firm posted $1.81 earnings per share. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Shareholders of record on Monday, June 15th were given a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s payout ratio is presently 44.69%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the completion of the sale, the insider owned 124,234 shares in the company, valued at $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 83,000 shares of company stock valued at $10,824,500 in the last three months. 0.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 price objective on shares of Gilead Sciences in a research note on Monday, July 6th. Citigroup raised their target price on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Weiss Ratings lowered shares of Gilead Sciences from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, May 28th. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Sunday. Finally, Royal Bank Of Canada cut their price objective on Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 7th. Twenty-six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $159.04.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.